Airsonett AB has a comprehensive patent portfolio and invests heavily in clinical research and product development. With strong owners, including SEB Venture Capital, Industrifonden and Magnus Lundberg, Airsonett is also investing in international growth.
The company was founded in the mid-1990s as part of a company that specialised in industrial clean room technology. TLA (Temperature controlled Laminar Airflow) technology, on which Airsonett’s products are based, evolved from industrial clean room technology. Airsonett AB was hived off into an independent company in 2000. The company’s main product is a non-pharmaceutical asthma treatment called Airsonett.
In recent years Airsonett AB has expanded internationally and now has operations in Scandinavia, Germany and the UK. Continued expansion is planned, primarily in the USA and Asia.
In 2010 Airsonett AB formed a new subsidiary, Airsonett Operating Room Innovation AB, which is now called Avidicare AB. Airsonett AB’s operations involving infection control in a surgical environment (Opragon®) were transferred to Avidicare AB.